Mutant KRAS conversion of conventional T cells into regulatory T cells

Stephanie Zdanov, Magis Mandapathil, Rasha Abu Eid, Saudat Adamson-Fadeyi, Willie Wilson, Jiahua Qian, Andrea Carnie, Nadya Tarasova, Mikayel Mkrtichyan, Jay A. Berzofsky, Theresa L. Whiteside, Samir N. Khleif

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Constitutive activation of the KRAS oncogene in human malignancies is associated with aggressive tumor growth and poor prognosis. Similar to other oncogenes, KRAS acts in a cell-intrinsic manner to affect tumor growth or survival. However, we describe here a different, cell-extrinsic mechanism through which mutant KRAS contributes to tumor development. Tumor cells carrying mutated KRAS induced highly suppressive T cells, and silencing KRAS reversed this effect. Overexpression of the mutant KRASG12V gene in wild-type KRAS tumor cells led to regulatory T-cell (Treg) induction. We also demonstrate that mutant KRAS induces the secretion of IL10 and transforming growth factor-b1 (both required for Treg induction) by tumor cells through the activation of the MEK-ERK-AP1 pathway. Finally, we report that inhibition of KRAS reduces the infiltration of Tregs in KRAS-driven lung tumorigenesis even before tumor formation. This cell-extrinsic mechanism allows tumor cells harboring a mutant KRAS oncogene to escape immune recognition. Thus, an oncogene can promote tumor progression independent of its transforming activity by increasing the number and function of Tregs. This has a significant clinical potential, in which targeting KRAS and its downstream signaling pathways could be used as powerful immune modulators in cancer immunotherapy.

Original languageEnglish (US)
Pages (from-to)354-365
Number of pages12
JournalCancer Immunology Research
Volume4
Issue number4
DOIs
StatePublished - Jan 1 2016

Fingerprint

Regulatory T-Lymphocytes
T-Lymphocytes
Neoplasms
Oncogenes
MAP Kinase Signaling System
Transforming Growth Factors
Growth
Interleukin-10
Immunotherapy
Carcinogenesis
Lung
Survival

ASJC Scopus subject areas

  • Immunology
  • Cancer Research

Cite this

Zdanov, S., Mandapathil, M., Eid, R. A., Adamson-Fadeyi, S., Wilson, W., Qian, J., ... Khleif, S. N. (2016). Mutant KRAS conversion of conventional T cells into regulatory T cells. Cancer Immunology Research, 4(4), 354-365. https://doi.org/10.1158/2326-6066.CIR-15-0241

Mutant KRAS conversion of conventional T cells into regulatory T cells. / Zdanov, Stephanie; Mandapathil, Magis; Eid, Rasha Abu; Adamson-Fadeyi, Saudat; Wilson, Willie; Qian, Jiahua; Carnie, Andrea; Tarasova, Nadya; Mkrtichyan, Mikayel; Berzofsky, Jay A.; Whiteside, Theresa L.; Khleif, Samir N.

In: Cancer Immunology Research, Vol. 4, No. 4, 01.01.2016, p. 354-365.

Research output: Contribution to journalArticle

Zdanov, S, Mandapathil, M, Eid, RA, Adamson-Fadeyi, S, Wilson, W, Qian, J, Carnie, A, Tarasova, N, Mkrtichyan, M, Berzofsky, JA, Whiteside, TL & Khleif, SN 2016, 'Mutant KRAS conversion of conventional T cells into regulatory T cells', Cancer Immunology Research, vol. 4, no. 4, pp. 354-365. https://doi.org/10.1158/2326-6066.CIR-15-0241
Zdanov S, Mandapathil M, Eid RA, Adamson-Fadeyi S, Wilson W, Qian J et al. Mutant KRAS conversion of conventional T cells into regulatory T cells. Cancer Immunology Research. 2016 Jan 1;4(4):354-365. https://doi.org/10.1158/2326-6066.CIR-15-0241
Zdanov, Stephanie ; Mandapathil, Magis ; Eid, Rasha Abu ; Adamson-Fadeyi, Saudat ; Wilson, Willie ; Qian, Jiahua ; Carnie, Andrea ; Tarasova, Nadya ; Mkrtichyan, Mikayel ; Berzofsky, Jay A. ; Whiteside, Theresa L. ; Khleif, Samir N. / Mutant KRAS conversion of conventional T cells into regulatory T cells. In: Cancer Immunology Research. 2016 ; Vol. 4, No. 4. pp. 354-365.
@article{96553163036b43ac98f2aa21511627a4,
title = "Mutant KRAS conversion of conventional T cells into regulatory T cells",
abstract = "Constitutive activation of the KRAS oncogene in human malignancies is associated with aggressive tumor growth and poor prognosis. Similar to other oncogenes, KRAS acts in a cell-intrinsic manner to affect tumor growth or survival. However, we describe here a different, cell-extrinsic mechanism through which mutant KRAS contributes to tumor development. Tumor cells carrying mutated KRAS induced highly suppressive T cells, and silencing KRAS reversed this effect. Overexpression of the mutant KRASG12V gene in wild-type KRAS tumor cells led to regulatory T-cell (Treg) induction. We also demonstrate that mutant KRAS induces the secretion of IL10 and transforming growth factor-b1 (both required for Treg induction) by tumor cells through the activation of the MEK-ERK-AP1 pathway. Finally, we report that inhibition of KRAS reduces the infiltration of Tregs in KRAS-driven lung tumorigenesis even before tumor formation. This cell-extrinsic mechanism allows tumor cells harboring a mutant KRAS oncogene to escape immune recognition. Thus, an oncogene can promote tumor progression independent of its transforming activity by increasing the number and function of Tregs. This has a significant clinical potential, in which targeting KRAS and its downstream signaling pathways could be used as powerful immune modulators in cancer immunotherapy.",
author = "Stephanie Zdanov and Magis Mandapathil and Eid, {Rasha Abu} and Saudat Adamson-Fadeyi and Willie Wilson and Jiahua Qian and Andrea Carnie and Nadya Tarasova and Mikayel Mkrtichyan and Berzofsky, {Jay A.} and Whiteside, {Theresa L.} and Khleif, {Samir N.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1158/2326-6066.CIR-15-0241",
language = "English (US)",
volume = "4",
pages = "354--365",
journal = "Cancer Immunity",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Mutant KRAS conversion of conventional T cells into regulatory T cells

AU - Zdanov, Stephanie

AU - Mandapathil, Magis

AU - Eid, Rasha Abu

AU - Adamson-Fadeyi, Saudat

AU - Wilson, Willie

AU - Qian, Jiahua

AU - Carnie, Andrea

AU - Tarasova, Nadya

AU - Mkrtichyan, Mikayel

AU - Berzofsky, Jay A.

AU - Whiteside, Theresa L.

AU - Khleif, Samir N.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Constitutive activation of the KRAS oncogene in human malignancies is associated with aggressive tumor growth and poor prognosis. Similar to other oncogenes, KRAS acts in a cell-intrinsic manner to affect tumor growth or survival. However, we describe here a different, cell-extrinsic mechanism through which mutant KRAS contributes to tumor development. Tumor cells carrying mutated KRAS induced highly suppressive T cells, and silencing KRAS reversed this effect. Overexpression of the mutant KRASG12V gene in wild-type KRAS tumor cells led to regulatory T-cell (Treg) induction. We also demonstrate that mutant KRAS induces the secretion of IL10 and transforming growth factor-b1 (both required for Treg induction) by tumor cells through the activation of the MEK-ERK-AP1 pathway. Finally, we report that inhibition of KRAS reduces the infiltration of Tregs in KRAS-driven lung tumorigenesis even before tumor formation. This cell-extrinsic mechanism allows tumor cells harboring a mutant KRAS oncogene to escape immune recognition. Thus, an oncogene can promote tumor progression independent of its transforming activity by increasing the number and function of Tregs. This has a significant clinical potential, in which targeting KRAS and its downstream signaling pathways could be used as powerful immune modulators in cancer immunotherapy.

AB - Constitutive activation of the KRAS oncogene in human malignancies is associated with aggressive tumor growth and poor prognosis. Similar to other oncogenes, KRAS acts in a cell-intrinsic manner to affect tumor growth or survival. However, we describe here a different, cell-extrinsic mechanism through which mutant KRAS contributes to tumor development. Tumor cells carrying mutated KRAS induced highly suppressive T cells, and silencing KRAS reversed this effect. Overexpression of the mutant KRASG12V gene in wild-type KRAS tumor cells led to regulatory T-cell (Treg) induction. We also demonstrate that mutant KRAS induces the secretion of IL10 and transforming growth factor-b1 (both required for Treg induction) by tumor cells through the activation of the MEK-ERK-AP1 pathway. Finally, we report that inhibition of KRAS reduces the infiltration of Tregs in KRAS-driven lung tumorigenesis even before tumor formation. This cell-extrinsic mechanism allows tumor cells harboring a mutant KRAS oncogene to escape immune recognition. Thus, an oncogene can promote tumor progression independent of its transforming activity by increasing the number and function of Tregs. This has a significant clinical potential, in which targeting KRAS and its downstream signaling pathways could be used as powerful immune modulators in cancer immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85014918867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014918867&partnerID=8YFLogxK

U2 - 10.1158/2326-6066.CIR-15-0241

DO - 10.1158/2326-6066.CIR-15-0241

M3 - Article

VL - 4

SP - 354

EP - 365

JO - Cancer Immunity

JF - Cancer Immunity

SN - 2326-6066

IS - 4

ER -